Acutaas Chemicals working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
132.62×132.62×111.27×122.31×127.59×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
88.98×88.98×90.06×111.06×116.58×
99.95×99.95×96.06×122.64×156.69×
121.65×121.65×105.27×110.73×87.48×
2.10×2.06×1.71×3.41×2.01×
0.76×0.76×0.76×0.77×0.87×
0.82×0.82×0.74×2.57×0.79×
0.61×0.61×0.51×0.97×0.53×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ACUTAAS₹3,976.70

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹32,558 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)127.59122.31111.27132.62132.62
Receivable Days (DSO)116.58111.0690.0688.9888.98
Payable Days (DPO)156.69122.6496.0699.9599.95
Cash Conversion Cycle (days)87.48110.73105.27121.65121.65
Working Capital Turnover2.013.411.712.062.10
Asset Turnover0.870.770.760.760.76
Cash Conversion (CFO/Net Income)0.792.570.740.820.82
CFO/EBITDA0.530.970.510.610.61
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.